10.20.10
A new study indicates Meriva, a patented complex of curcumin with soy phosphatidylcholine from Indena, helps reduce frequency and severity of relapses in patients with recurrent anterior uveitis (RAU).
Published in Clinical Ophthalmology, this study shows that Meriva can play an important role in the adjunctive therapy of RAU, the most common form of uveitis, a form of inflammation involving the interior of the eye that in some cases can lead to blindness. Symptoms of RAU—also termed iritis—include pain, redness, photophobia and, to a variable degree, decreased vision.
Researchers administered two tablets of Norflo (Eye Pharma Co, Italy) containing 600 mg of Meriva each for 12 months to 122 patients diagnosed with RAU for at least two years before the beginning of the trial, and during which they had suffered 1-4 relapses per year.
Within the 106 patients who completed the study, only 19 (18%) had relapses. An improvement in symptoms including ocular pain and blurring of vision was also observed, and 86% of patients reported a subjective systemic well-being, progressively developed after 4-6 weeks of treatment. For further Information: www.indena.com
